Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Abemaciclib

FDA-approved product (tablet, oral), marketed as Verzenio.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Abemaciclib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • HER2 Positive Breast Carcinoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Cyclin-dependent kinase (cdk) inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA66.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli48.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae33.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis66.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Abemaciclib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Abemaciclib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer

    NCT02763566 · start 2016-12-05

    Registered record
    Registry ID
    NCT02763566
    Conditions
    Breast Cancer
    Interventions
    Abemaciclib; Anastrozole; Letrozole; Placebo; Fulvestrant
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2016-12-05
    Completion
    2028-03
    Enrolment
    463

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionAbemaciclib; Anastrozole; Letrozole; Placebo +1 more
    PhasePhase 3
    Registry statusActive not recruiting

  • A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors

    NCT02791334 · start 2016-06-29

    Registered record
    Registry ID
    NCT02791334
    Conditions
    Solid Tumor; Microsatellite Instability-High (MSI-H) Solid Tumors; Cutaneous Melanoma; Pancreatic Cancer; Breast Cancer (HR+HER2-)
    Interventions
    LY3300054; Ramucirumab; Abemaciclib; Merestinib; LY3321367
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-06-29
    Completion
    2024-06-27
    Enrolment
    164

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumor; Microsatellite Instability-High (MSI-H) Solid Tumors; Cutaneous Melanoma; Pancreatic Cancer +1 more
    InterventionLY3300054; Ramucirumab; Abemaciclib; Merestinib +1 more
    PhasePhase 1
    Registry statusCompleted

  • Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors

    NCT02644460 · start 2016-02

    Registered record
    Registry ID
    NCT02644460
    Conditions
    Diffuse Intrinsic Pontine Glioma; Brain Tumor, Recurrent; Solid Tumor, Recurrent; Neuroblastoma, Recurrent, Refractory; Ewing Sarcoma, Recurrent, Refractory; Rhabdomyosarcoma, Recurrent, Refractory; Osteosarcoma, Recurrent, Refractory; Rhabdoid Tumor, Recurrent, Refractory
    Interventions
    Abemaciclib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-02
    Completion
    2023-10-10
    Enrolment
    53

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiffuse Intrinsic Pontine Glioma; Brain Tumor, Recurrent; Solid Tumor, Recurrent; Neuroblastoma, Recurrent, Refractory +4 more
    InterventionAbemaciclib
    PhasePhase 1
    Registry statusCompleted

  • Study of LY2835219 for Mantle Cell Lymphoma

    NCT01739309 · start 2013-03-20

    Registered record
    Registry ID
    NCT01739309
    Conditions
    Mantle Cell Lymphoma
    Interventions
    Abemaciclib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-03-20
    Completion
    2022-09-05
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMantle Cell Lymphoma
    InterventionAbemaciclib
    PhasePhase 2
    Registry statusCompleted

  • Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

    NCT03763604

    Registered record
    Registry ID
    NCT03763604
    Conditions
    Metastatic Breast Cancer
    Interventions
    Abemaciclib
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    Approved for marketing
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    InterventionAbemaciclib
    PhaseNot recorded
    Registry statusApproved for marketing